Criminal activity surrounding the manufacture, distribution and sale of falsified medicines is “on the rise” as a global health problem in many developing countries and in rich nations – especially online – but efforts to stem the growing health threat will require robust collective action by all stakeholders, a leading Novartis official warned Friday in […] Continue reading ->
The issues around access to medicines at affordable prices has galvanized civil society, the pharmaceutical industry, the research community, and politicians this year in oft-contentious debate that shows no sign of abating. A day-long session hosted by the Global Health Centre of Geneva’s Graduate Institute, and cosponsored by the Swiss Institute of Intellectual Property and […] Continue reading ->
For the second year running, some 37 organizations have launched a week-long mini campaign to raise awareness and promote action against falsified and substandard medicines.  This year’s annual Fight the Fakes week aims to mobilize the public and international global health community to speak up more assertively about the growing threat of fake or substandard […] Continue reading ->
A new knowledge hub Global Health Progress, highlighting over 200 collaborations between the biopharmaceutical industry involving more than 850 government, multilateral organization and civil society partners, was launched Friday by the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA). The hub provides a worldwide mapping of health-related initiatives in which IFPMA members are engaged, searchable […] Continue reading ->
Kawaldip Sehmi, CEO of the International Alliance of Patients’ Organizations (IAPO), answers 5 questions on why the Essential Medicines List is important for patients. IAPO is a United Kingdom-based alliance of 276 member organisations from 71 countries representing 50 disease areas, and working in collaboration with civil society, UN agencies and the healthcare industry. Sehmi holds a […] Continue reading ->
WHO has added ten new cancer drugs, including some pricey ones, to its 2019 Essential Medicines List, which provides global guidance to countries and health systems about drugs deemed most essential to patients and public health systems. The addition of major new cancer treatments in five categories, melanoma (skin), lung, blood and prostate cancers, reflects […] Continue reading ->
Githinji Gitahi, Co-Chair of the UHC2030 Steering Committee & Group Chief Executive Officer of AMREF Health Africa – the largest Africa-based healthcare non-profit – and Fumie Griego, Deputy Director General and Chief Operating Officer of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), share highlights from a panel discussion held in Geneva on the […] Continue reading ->
In a little-publicised move, the WHA last week agreed to close a critical loophole in the WHO Pandemic Influenza Preparedness (PIP) Framework that could have allowed commercial vaccine manufacturers to indirectly make use of biological information about flu strains from another country – without providing that country with any benefits from the vaccines or antivirals […] Continue reading ->
After a grueling 34 hours of nearly non-stop negotiations, World Health Assembly delegates appeared to be close to a final agreement Saturday evening on a resolution supporting more systematic disclosure of prices for medicines purchased and sold on national and global markets; a “drafting group” is expected to reconvene Monday morning to put the finishing […] Continue reading ->